The Swiss life sciences supplier announced the approval this morning in a filing on the Swiss SIX Exchange.
A Lonza spokeswoman told us “all regulatory approvals required have now been obtained. These approvals include, among others, the US and EU. All approvals were without any requirements for divestments, and without any other limitations/caveats or the like.”
She added that “The actual closing is expected in the next days, subject to satisfying customary closing conditions.”
In December, Lonza said buying Capsugel will help it achieve operating synergies of CHF30m a year in three years, citing corporate, procurement and IT infrastructure as areas in which savings will be made.
The Swiss firm also predicted “tax synergies” of CHF15m a year and “efficiency gains” as a result of the deal.
Previously Lonza has said Capsugel's business units - biopharmaceuticals and consumer health & nutrition - will report into its Pharma&Biotech and Specialty Ingredients divisions, respectively.
In March, Lonza hinted the integration of Capsugel would see its Pharma&Biotech segment grow in importance in 2017.
The firm said “Capsugel will accelerate growth and deliver value along the healthcare continuum by complementing our existing offerings and by opening up new market opportunities in the pharma and consumer healthcare and nutrition industries.”